LONGECITY

http://www.neurophar...om/podcast.html

http://www.journals....ogy-conference/
http://www.neurophar...e.elsevier.com/

Would be great to have in a discussion like this on cognitive enhancers the scientist from UCB pharmaceuticals.
(the people who developed the piracetam)

Piracetam was developed in the mid-1960's by UCB pharmaceutical company of Belgium to treat motion sickness. (1) Between 1968 and 1972, however, there was an explosion of Piracetam research which uncovered its ability to facilitate learning, prevent amnesia induced by hypoxia and electroshock, and accelerate electroencephalograph return to normal in hypoxic animals. (1) By 1972 700 papers were published on Piracetam. (1) Yet already by 1972 Piracetam's pharmacologic uniqueness led C.E. Giurgea, UCB's principal Piracetam researcher and research coordinator, to formulate an entirely new category of drugs to describe Piracetam: the nootropic drug. (2)

http://en.wikipedia....eliu_E._Grudge
Gary lynch is also one of the conference speakers.
http://www.anatomy.uci.edu/lynch.html

What do you guys think about the transcript? did you think it was a well rounded and balanced discussion?

is anyone interested in going to this event?

Cognitive Enhancers: 22^nd Neuropharmacology Conference

Official Satellite to the 2012 Meeting of the Society for Neuroscience

Hilton Riverside, New Orleans, LA, USA | 11-12 October 2012<p>


Conference Chairs

Gary Lynch, University of California, Irvine, CA, USA
Barbara Sahakian, University of Cambridge, UK
Conference Organizing Committee

Graham Collingridge, University of Bristol, UK
Jacqueline Crawley, UC Davis MIND Institute, USA
Jeffrey Nye, Johnson & Johnson, USA
Keynote Speakers

Susumu Tonegawa, MIT, Cambridge, MA, USA
Richard Morris, University of Edinburgh, UK
Cognitive enhancement has become a subject of considerable research and, both in neuroscience and society at large, growing controversy. This satellite meeting will survey progress in the field from attempts to facilitate the substrates of memory and cognition in animal models to clinical studies targeted at major psychiatric disorders. Attendees will accordingly have a first-hand opportunity to learn about the broad spectrum of enhancement research ranging from epigenetics through synaptic plasticity and brain networks to behavior. Individual sessions include both cutting edge work on currently marketed drugs and experiments using novel, mechanism-based compounds. The program will therefore be of interest to those interested in present and future therapeutic prospects for autism, age-related cognitive decline, addiction, and depression. It also directly addresses the possibility of enhancement in normal subjects, a contentious issue that affects much of the neuroscience community.
Topics List

Papers are invited on the following conference themes:

• Enhancing brain substrates of cognition:
  
  • Plasticity and memory
  • Cortical systems
• Enhancement as a treatment for cognitive disorders:
  
  • Aging
  • Spine dysfunction
  • Experience and epigenetics
  • Affective disorders
  • Schizophrenia
  • Autism spectrum disorders
  • http://www.neuropharmacology-conference.elsevier.com

Edited by CIMN, 21 August 2012 - 04:45 PM.

You didn't get noticed. Bump for substance.

I hope Lynch updates us on some ampakine research.

I hope Lynch updates us on some ampakine research.

I have the handout from a recent conference on Dietetics and Aging. A presentation lasting an hour and fifteen minutes titled "Nutraceuticals and Cognitive Performance in Aging populations" discussed supplements already known on the boards.

B12
SAMe
N Acetyl Cystine
Turmeric
CoQ10
MGTs such as Coconut Oil and Caprylic acid

and a couple of others